Form D · Biotechnology
Abata Therapeutics, Inc.
Watertown, MA · CIK 0001867989
Offering snapshot reported Dec 27, 2023 · SEC filing
- Reported sold
- $15.3M Indefinite offering
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Dec 14, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 27, 2023 | Initial | $15,332,894 | No comparison | 8 | SEC filing |
| Jun 16, 2022 | Amendment | $45,000,000 | $0vs Jun 21, 2021 | 7 | SEC filing |
| Jun 21, 2021 | Initial | $45,000,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- Yes
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-500774
Source: Form D, filed Dec 27, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ellen Cahir Mcfarland | Executive |
| Abbie Celniker | Director |
| Shelley Chu | Director |
| Leonard Dragone | Executive |
| Mitch Finer | Director |
| David Kaufman | Director |
| Lorence Kim | Director |
| Sandy Lazzari | Executive |
| Nagesh Mahanthappa | Director |
| Valerie Odegard | Director |
| Samantha Singer | Director, Executive |
| Stephen Sofen | Executive |
| John Trzupek | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
100 Forge Road Suite 200
Watertown, MA, 02472
Watertown, MA, 02472